Scemblix (Asciminib)
CML Chronic Myeloid Leukemia
"SCEMBLIX® (asciminib) tablets is a prescription medicine used to treat adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitor (TKI) medicines. The effectiveness of SCEMBLIX in these patients is based on a study that measured major molecular response (MMR) rates. No clinical information is available to show if these patients treated with SCEMBLIX live longer or if their symptoms improve. Ongoing studies exist to find out how SCEMBLIX works over a longer period of time.
SCEMBLIX is also approved for use in adults with Ph+ CML in CP with the T315I mutation."
Extract of FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia, October 29, 2021, Novartis
VIDEOS
Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML
December 2022, OncologyTube.com
Phase I study of asciminib in patients with CP-CML carrying the T315I mutation
October 21, 2022, VJHemOnc – Video Journal of Hematological Oncology
CML: Asciminib Use in Later-Line Chronic Myeloid Leukemia
February 9, 2022, OncLive
Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukemia
January 12, 2022, ecancer
New TKI Therapy Shows Promise for Patients with Recurrent CML
Decembre 14, 2021, Patient Power
New Longer-term Efficacy, Safety Data of Asciminib in CML
December 11, 2021, Pharmacy Times
Medical Session #2 CML Horizons 2021 - Update on asciminib - Andreas Hochhaus.
October 2021, CML Advocates Network
Dr. Jorge Cortes: First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation
January 4, 2021, ecancer
Andreas Hochhaus: Asciminib for hard-to-treat chronic myeloid leukaemia
January 4, 2021, ecancer
Michael Savona, MD, regarding the ASCEMBL study presented at ASH 2020
Dec 10, 2020, OBR_Oncology
Andreas Hochhaus: Asciminib vs. Bosutinib in Chronic Myeloid Leukemia
December 4, 2020, American Society of Hematology
Asciminib: overcoming TKI resistance and reducing toxity in CML (Dr. Timothy Hughes)
September 14, 2018, VJHemOnc – Video Journal of Hematological Oncology
Asciminib plus traditonal TKIs for chronic phase CML (Dr. Giuseppe Saglio)
September 13, 2018, VJHemOnc – Video Journal of Hematological Oncology
Fourth generation TKIs for CML: asciminib (Dr. Michael Mauro)
September 13, 2018, VJHemOnc – Video Journal of Hematological Oncology
Asciminib has the potential to succeed where other TKIs have failed in CML (Dr. Timothy Hughes)
August 15, 2018, VJHemOnc – Video Journal of Hematological Oncology
CML Horizons 2018. SUN09 ABL001 Ascitinib trials. (Dr. Delphine Rea)
May 28, 2018, CML Advocates Network
Dr. Nguyen on ABL001 in Patients With CML
February 5, 2016, OncLiveTV
Future of CML - ABL001 and other treatments in the pipeline
2016, CML Advocates Network
VIDEOS
Asciminib: ASH 2022 Prof. Hughes Studies For Pts With CML
December 2022, OncologyTube.com
Phase I study of asciminib in patients with CP-CML carrying the T315I mutation
October 21, 2022, VJHemOnc – Video Journal of Hematological Oncology
CML: Asciminib Use in Later-Line Chronic Myeloid Leukemia
February 9, 2022, OncLive
Asciminib found to be safe and effective for heavily pretreated patients with chronic myeloid leukemia
January 12, 2022, ecancer
New TKI Therapy Shows Promise for Patients with Recurrent CML
Decembre 14, 2021, Patient Power
New Longer-term Efficacy, Safety Data of Asciminib in CML
December 11, 2021, Pharmacy Times
Medical Session #2 CML Horizons 2021 - Update on asciminib - Andreas Hochhaus.
October 2021, CML Advocates Network
Dr. Jorge Cortes: First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation
January 4, 2021, ecancer
Andreas Hochhaus: Asciminib for hard-to-treat chronic myeloid leukaemia
January 4, 2021, ecancer
Michael Savona, MD, regarding the ASCEMBL study presented at ASH 2020
Dec 10, 2020, OBR_Oncology
Andreas Hochhaus: Asciminib vs. Bosutinib in Chronic Myeloid Leukemia
December 4, 2020, American Society of Hematology
Asciminib: overcoming TKI resistance and reducing toxity in CML (Dr. Timothy Hughes)
September 14, 2018, VJHemOnc – Video Journal of Hematological Oncology
Asciminib plus traditonal TKIs for chronic phase CML (Dr. Giuseppe Saglio)
September 13, 2018, VJHemOnc – Video Journal of Hematological Oncology
Fourth generation TKIs for CML: asciminib (Dr. Michael Mauro)
September 13, 2018, VJHemOnc – Video Journal of Hematological Oncology
Asciminib has the potential to succeed where other TKIs have failed in CML (Dr. Timothy Hughes)
August 15, 2018, VJHemOnc – Video Journal of Hematological Oncology
CML Horizons 2018. SUN09 ABL001 Ascitinib trials. (Dr. Delphine Rea)
May 28, 2018, CML Advocates Network
Dr. Nguyen on ABL001 in Patients With CML
February 5, 2016, OncLiveTV
Future of CML - ABL001 and other treatments in the pipeline
2016, CML Advocates Network
CLINICAL TRIALS
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
July 6, 2018, ClinicalTrials.gov
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
May 25, 2018, ClinicalTrial.gov
A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL
May 4, 2018, ClinicalTrial.gov
CABL001X2101 = A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With CML or Ph+ ALL
March 29, 2018, CML Advocates Network
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) – Australian Cancer Trial
2018, MDAnderson Cancer Center
Phase I Study of oral ABL001 in patients with CML or Ph+ALL
February7, 2018, European Leukemia Trial Registry
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
April 10, 2017, ClinicalTrial.gov
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
July 6, 2018, ClinicalTrials.gov
A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors
May 25, 2018, ClinicalTrial.gov
A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL
May 4, 2018, ClinicalTrial.gov
CABL001X2101 = A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With CML or Ph+ ALL
March 29, 2018, CML Advocates Network
A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) – Australian Cancer Trial
2018, MDAnderson Cancer Center
Phase I Study of oral ABL001 in patients with CML or Ph+ALL
February7, 2018, European Leukemia Trial Registry
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
April 10, 2017, ClinicalTrial.gov
ABSTRACTS FROM ASH 2022
Two-Year Updated Results of Asciminib Managed-Access Program (MAP) in Russia
ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors
ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)
ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase
Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA
Select P-Loop Mutants in BCR::ABL1 Confer Moderate to High Degrees of Resistance to Asciminib
Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study
Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia
Population Pharmacokinetics in Hepatic and Renal Impairment and PBPK Drug-Drug Interaction Simulations of Asciminib, a Novel Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia in Chronic Phase
Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
Real-World Experience of Asciminib: Factors Associated with Response
Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML-CP) with and without the T315I Mutation
Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML – Interim Results from ALLG CML13 Ascend-CML
Two-Year Updated Results of Asciminib Managed-Access Program (MAP) in Russia
ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors
ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)
ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase
Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA
Select P-Loop Mutants in BCR::ABL1 Confer Moderate to High Degrees of Resistance to Asciminib
Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study
Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia
Population Pharmacokinetics in Hepatic and Renal Impairment and PBPK Drug-Drug Interaction Simulations of Asciminib, a Novel Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia in Chronic Phase
Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors
Real-World Experience of Asciminib: Factors Associated with Response
Justification for Asciminib Dosing in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (Ph+ CML-CP) with and without the T315I Mutation
Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML – Interim Results from ALLG CML13 Ascend-CML
ARTICLES
Asciminib vs Bosutinib in Chronic Myeloid Leukemia Treatment
November 4, 2022, Cancer Network
Novartis Scemblix®, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia
August 29, 2022, Novartis
European Commission Approves Asciminib in Philadelphia Chromosome–Positive CML
August 29, 2022, Cancer Network
Asciminib Improves Efficacy vs Other Third-Line Treatments in Chronic Phase CML
July 22, 2022, Targeted Oncology
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
June 24, 2022, Novartis
Expert Commentary on the Product Profile of Asciminib
April 8, 2022, CancerNetwork
Asciminib Shows Superior Efficacy to Bosutinib for Patients With CML in Chronic Phase
January 20, 2022, Hematology Advisor
Comparing Asciminib With Bosutinib in Patients With Chronic-Phase Chronic Myeloid Leukemia
December 17, 2021, DocWireNews
Patients With Chronic-Phase CML Achieved Deeper, More Durable Molecular Responses With Asciminib Vs Bosutinib
December 13, 2021, CancerNetwork
Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia
December 11, 2021, GlobeNewswire
FDA Approves Scemblix for Pretreated CML in the Chronic Phase
October 29, 2021, Cure Today
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
October 29, 2021, Novartis
FDA Accelerates Review of Asciminib for Patients with Chronic Myeloid Leukemia
August 27, 2021, Pharmacy Times
FDA Grants Priority Review to Asciminib for Chronic Myeloid Leukemia
August 25, 2021, OncLive
A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs
August 18, 2021, ASH Publications - Blood
Asciminib for the Treatment of Patients With Chronic Myeloid Leukemia
April 2021, Clinical Advances in Hematology and Oncology
Asciminib in chronic myeloid leukemia: many questions still remain to be answered
April 29, 2021, Blood Journal Cancer
FDA Grants Breakthrough Therapy Designation to Asciminib for 2 CML Indications
February 10,2021, Cancer Network
FDA Grants Breakthrough Therapy Designations to Asciminib for CML
February 9, 2021, OncLive
FDA Grants 2 Breakthrough Therapy Designations to Asciminib in Ph+ CML
February 8, 2021, Targeted Therapy
Novartis eyes 2021 regulatory submissions for ‘STAMP’ inhibitor asciminib
December 9, 2020, PMLive
Asciminib Represents New Safe and Effective Treatment Option for Heavily Pretreated CML
December 6, 2020, Targeted Oncology
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase
November 2020, Leukemia Research
Novartis Push To Expand Cancer Arsenal Gets Trial Win Against Pfizer Bosulif
August 28, 2020, Medical Dialogues
Novartis reports positive data of asciminib in ASCEMBL trial
August 27, 2020, Clinical Trials Arena
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
August 26, 2020, PipelineReview.com
Novel ABL1 Kinase Inhibitor Active in Heavily Pretreated CML
January 27, 2020, Oncology Learning Network
Asciminib Shows Clinical Activity for Pretreated CML in Phase 1 Trial
January 13, 2020, Cancer Therapy Advisor
Asciminib Active in Patients With Heavily Pretreated CML
January 6, 2020, Oncology Learning Network
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
December 12, 2019, The New England Journal of Medicine
Step forward in leukemia treatment
December 12, 2019, South Australian Health and Medical Research Institute
Leukaemia breakthrough as scientists find drug can fight the blood cancer without causing toxic side effects seen in currently-used medications
December 11, 2019, Daily Mail Health
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
September 4, 2019, PubMed
Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial
December 3, 2018, ASH2018
Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
August 18, 2017, Europe PMC
Double trouble for CML - ABL001 and TKIs
April 5, 2017, Science Translational Médicine
Striving to vanquish leukemia
March 22,2017, Novartis
'Promising' CML phase I results for ABL001 BCR-ABL inhibitor
December 2016, iCMLf
A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells
December 6, 2016, ASH2016
Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy
December 2, 2016, ASH 2016
ABL001 May Be Active, Safe in Chronic Leukemia After Failure of Prior TKI Therapy
December 6, 2015, Cancer Therapy Advisor
ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy
2015, Journal Blood
Bull's-Eyes and Blind Spots: Pre-Clinical Studies with the Allosteric Inhibitor ABL001 in BCR-ABL1 Compound Mutation-Based Resistance
2015, Journal Blood
ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia
2014, Journal Blood
Asciminib vs Bosutinib in Chronic Myeloid Leukemia Treatment
November 4, 2022, Cancer Network
Novartis Scemblix®, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia
August 29, 2022, Novartis
European Commission Approves Asciminib in Philadelphia Chromosome–Positive CML
August 29, 2022, Cancer Network
Asciminib Improves Efficacy vs Other Third-Line Treatments in Chronic Phase CML
July 22, 2022, Targeted Oncology
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
June 24, 2022, Novartis
Expert Commentary on the Product Profile of Asciminib
April 8, 2022, CancerNetwork
Asciminib Shows Superior Efficacy to Bosutinib for Patients With CML in Chronic Phase
January 20, 2022, Hematology Advisor
Comparing Asciminib With Bosutinib in Patients With Chronic-Phase Chronic Myeloid Leukemia
December 17, 2021, DocWireNews
Patients With Chronic-Phase CML Achieved Deeper, More Durable Molecular Responses With Asciminib Vs Bosutinib
December 13, 2021, CancerNetwork
Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia
December 11, 2021, GlobeNewswire
FDA Approves Scemblix for Pretreated CML in the Chronic Phase
October 29, 2021, Cure Today
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
October 29, 2021, Novartis
FDA Accelerates Review of Asciminib for Patients with Chronic Myeloid Leukemia
August 27, 2021, Pharmacy Times
FDA Grants Priority Review to Asciminib for Chronic Myeloid Leukemia
August 25, 2021, OncLive
A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs
August 18, 2021, ASH Publications - Blood
Asciminib for the Treatment of Patients With Chronic Myeloid Leukemia
April 2021, Clinical Advances in Hematology and Oncology
Asciminib in chronic myeloid leukemia: many questions still remain to be answered
April 29, 2021, Blood Journal Cancer
FDA Grants Breakthrough Therapy Designation to Asciminib for 2 CML Indications
February 10,2021, Cancer Network
FDA Grants Breakthrough Therapy Designations to Asciminib for CML
February 9, 2021, OncLive
FDA Grants 2 Breakthrough Therapy Designations to Asciminib in Ph+ CML
February 8, 2021, Targeted Therapy
Novartis eyes 2021 regulatory submissions for ‘STAMP’ inhibitor asciminib
December 9, 2020, PMLive
Asciminib Represents New Safe and Effective Treatment Option for Heavily Pretreated CML
December 6, 2020, Targeted Oncology
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase
November 2020, Leukemia Research
Novartis Push To Expand Cancer Arsenal Gets Trial Win Against Pfizer Bosulif
August 28, 2020, Medical Dialogues
Novartis reports positive data of asciminib in ASCEMBL trial
August 27, 2020, Clinical Trials Arena
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
August 26, 2020, PipelineReview.com
Novel ABL1 Kinase Inhibitor Active in Heavily Pretreated CML
January 27, 2020, Oncology Learning Network
Asciminib Shows Clinical Activity for Pretreated CML in Phase 1 Trial
January 13, 2020, Cancer Therapy Advisor
Asciminib Active in Patients With Heavily Pretreated CML
January 6, 2020, Oncology Learning Network
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
December 12, 2019, The New England Journal of Medicine
Step forward in leukemia treatment
December 12, 2019, South Australian Health and Medical Research Institute
Leukaemia breakthrough as scientists find drug can fight the blood cancer without causing toxic side effects seen in currently-used medications
December 11, 2019, Daily Mail Health
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
September 4, 2019, PubMed
Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor, in Patients with Chronic Myeloid Leukemia Carrying the T315I Mutation in a Phase 1 Trial
December 3, 2018, ASH2018
Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
August 18, 2017, Europe PMC
Double trouble for CML - ABL001 and TKIs
April 5, 2017, Science Translational Médicine
Striving to vanquish leukemia
March 22,2017, Novartis
'Promising' CML phase I results for ABL001 BCR-ABL inhibitor
December 2016, iCMLf
A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells
December 6, 2016, ASH2016
Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy
December 2, 2016, ASH 2016
ABL001 May Be Active, Safe in Chronic Leukemia After Failure of Prior TKI Therapy
December 6, 2015, Cancer Therapy Advisor
ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy
2015, Journal Blood
Bull's-Eyes and Blind Spots: Pre-Clinical Studies with the Allosteric Inhibitor ABL001 in BCR-ABL1 Compound Mutation-Based Resistance
2015, Journal Blood
ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia
2014, Journal Blood
See also Mutation T315I
